Peptide
Semaglutide
STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.
Één pagina per medicijn. Effectgroottes, onderzoeksopzetten en de populaties waarin ze zijn gemeten.
Peptide
STEP 1 to STEP 5, SELECT, and roughly 15% mean weight loss in obesity without diabetes.
Dual agonist
SURMOUNT-1 and -2, sleep apnoea and heart failure, and about 21% mean weight loss.
Oral
Oral semaglutide and orforglipron — the same mechanism without the injection.
Intermittent fasting, time-restricted eating and meal timing, judged on the trial data.
Energy expenditure, insulin resistance and metabolic adaptation, without the folklore.
Diets, drugs, behaviour and maintenance — ranked by the strength of the evidence behind them.
Sleep, circadian rhythm and the wearables that claim to measure both.
Deze pagina is automatisch vertaald vanuit het Engels. De citaten en nummers zijn onveranderd. Lees het Engelse origineel als iets vreemd leest. Lees het Engelse origineel